AP Biosciences Inc (TPEX: 6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
50.20
+0.20 (0.40%)
Nov 20, 2024, 12:53 PM CST
-4.74%
Market Cap 4.26B
Revenue (ttm) 32.25M
Net Income (ttm) -447.49M
Shares Out 84.87M
EPS (ttm) -6.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,491
Open 49.80
Previous Close 50.00
Day's Range 49.80 - 50.20
52-Week Range 41.05 - 70.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2024

About AP Biosciences

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast ca... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.